In the next two decades, U.S. rankings of the most common and deadly cancer types will shift, reflecting the influence of screening programs and advancements in treatment.
Lola Rahib, PhD, Director of Scientific and Clinical Affairs at Cancer Commons, led this research, which appears today in JAMA Network Open. The projections were prepared in collaboration with the Pancreatic Cancer Action Network (PanCAN) and The University of Texas MD Anderson Cancer Center.